InflaRx Reports Results of Vilobelimab in the P-III Part of P-II/III (PANAMO) Study for the Treatment of Severe COVID-19
Shots:
- The P-III part of the P-II/III (PANAMO) study evaluates vilobelimab vs PBO in a ratio (1:1) in 369 patients with COVID-19 across sites in the EU, South America & other regions
- The results showed a (31.7% vs 41.6%) relative reduction in 28-day all-cause mortality of 23.9% but failed to show statistical significance on the pre-specified 1EPs. The 2EPs showed a reduction of mortality (36.5% vs 47.2%) in 60 days of all-cause mortality, were safe & well-tolerated
- A pre-specified analysis from Western EU countries (n=209) showed a (21.2% vs 37.2%) relative reduction in 28-day all-cause mortality of 43%. The company plans to discuss with regulatory authorities to define the next steps of vilobelimab
Ref: Globe Newswire | Image: Globe Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
